The CFO appointment is a routine executive transition following an interim period. While the $5 million in equity grants represents a significant compensation package, the appointment itself is expected to ensure leadership continuity rather than signal a strategic shift. Traders should monitor the company's progress toward product commercialization, as this triggers vesting of a significant portion of DeTore's performance stock units.
CGON drugs
CGON drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 13 $67.70entry
- T+1 · 7mo ago −0.62%α −1.83% · $67.28
- T+5 · 7mo ago +3.99%α +0.69% · $70.40
- T+20 · 6mo ago +2.39%α −5.34% · $69.32
- T+60 · 4mo ago +3.10%α −5.82% · $69.80
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CG Oncology appointed Jim DeTore as Chief Financial Officer, effective April 13, 2026. The appointment follows his interim role since November 2025 and includes a formal employment agreement with a $520,000 annual base salary and $5 million in initial equity awards.
Key Facts
- Jim DeTore was formally appointed Chief Financial Officer effective April 13, 2026
- DeTore had been serving as Interim Principal Financial and Accounting Officer since November 2025
- He receives a $520,000 annual base salary and is eligible for a 45% target annual bonus
- He received an initial stock option grant valued at $4 million and a performance stock unit award valued at $1 million
- The PSU award vests 30% upon first U.S. commercial sale of the company's first approved product and 70% upon achievement of positive operating cash flow for two consecutive quarters post-launch
Financial Impact
Initial equity awards totaling $5 million ($4 million stock options, $1 million in PSUs) and $520,000 annual base salary
Risk Factors
- Potential for executive turnover if performance expectations are not met
- Dilution from the $5 million in new equity grants
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-152044 |
| Document: ck0001991792-20260413.htm | 0001193125-26-152044 |
| Document: 0001193125-26-152044-index-headers.html | 0001193125-26-152044 |
| Document: 0001193125-26-152044-index.html | 0001193125-26-152044 |
| Document: 0001193125-26-152044.txt | 0001193125-26-152044 |
Track record
25 reports on CGON
6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +26.33% at T+20 after the Jun 12, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 16, 2026today 8-K Bullish 7/10 Entry $98.84 Now $84.78 −14.23% settles Dec 15
- Nov 16, 2026today Press Release Bullish 7/10 Entry $95.01 Now $84.78 −10.77% settles Dec 15
- Nov 6, 202610d ago 8-K Bearish 5/10 Entry $75.99 Now $84.78 −11.57% settles Dec 7
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $75.99 Now $84.78 +11.57% settles Dec 7
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $64.06 Now $84.78 +32.34% settles Dec 2
- Oct 19, 202628d ago 3 Neutral 2/10 Entry $61.93 Now $84.78 +36.90% settles Nov 17
- Oct 15, 20264w ago 144 Neutral 2/10 Entry $59.85 to $74.40 Now $84.78 +41.65% ▲ +24.31% +25.47% vs SPY
- Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $63.13 to $74.74 Now $84.78 +34.29% ▲ +18.39% +21.66% vs SPY
- Aug 6, 202614w ago Press Release Bearish 7/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
- Aug 6, 202614w ago 424B5 Bearish 6/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers